Ajooni Biotech confirms no encumbrance on promoter shares in FY26

Ajooni Biotech has submitted a disclosure to the National Stock Exchange regarding the shareholding status of its promoters for the financial year ended March 31, 2026. The company confirmed that its promoters and persons acting in concert have not created any encumbrance over the shares held by them, directly or indirectly, during this period. The announcement was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011.

The disclosure, dated April 03, 2026, was submitted on behalf of all promoters. It explicitly states that no shares were encumbered during FY26. The document was signed by Jasjot Singh, the Managing Director, on behalf of the promoters. The company subsequently forwarded the yearly disclosure to the exchange on April 04, 2026, for record-keeping purposes.

Promoter Details

The filing included an annexure listing the individuals classified as promoters and members of the promoter group. The list was signed by Jasjot Singh on April 03, 2026.

Promoters

S.No.	Name
1	JASJOT SINGH

Promoter Group

S.No.	Name
1	PARMJEET KAUR
2	UPNEET KAUR
2	ASHMEET KAUR
4	ISHNEET KAUR

The confirmation was addressed to the National Stock Exchange of India Ltd at Bandra-Kurla Complex, Mumbai. A copy of the communication was also marked to the Audit Committee of Ajooni Biotech Limited. The company’s registered office is located in Mohali, Punjab.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.73%	-2.13%	-4.62%	-13.60%	-30.24%	-53.96%

Ajooni Biotech , a player in the biotech sector, has made significant strides in its operational expansion, marking a new chapter in the company's growth trajectory. The firm has announced two major developments that are set to bolster its market position and revenue streams.

New Manufacturing Facility

Ajooni Biotech has commenced commercial production at its newly established manufacturing facility located in Khanna. This strategic move represents a significant expansion of the company's operational capabilities, potentially enhancing its production capacity and market reach.

Secured Contracts

In a parallel development, the company has successfully obtained cattle feed supply contracts, amounting to a substantial ₹27.00 crores. This achievement not only secures an immediate revenue stream for Ajooni Biotech but also demonstrates the market's confidence in the company's products and capabilities.

Impact on Business Operations

The dual announcement of the new facility and secured contracts paints a picture of robust growth for Ajooni Biotech. Here's a breakdown of the key implications:

Aspect	Details
Operational Expansion	New manufacturing facility in Khanna
Revenue Generation	Secured contracts worth ₹27.00 crores
Product Focus	Cattle feed supply
Immediate Impact	Commencement of commercial production

These developments suggest that Ajooni Biotech is positioning itself for increased market presence and enhanced production capabilities in the biotech and animal feed sectors.

The commencement of operations at the new facility, coupled with a significant order book, indicates that Ajooni Biotech is entering a phase of operational growth. The secured contracts provide a stable foundation for near-term revenue, while the new manufacturing capacity could support long-term expansion plans.

As Ajooni Biotech moves forward with these developments, stakeholders will likely be watching closely to see how these operational advancements translate into financial performance and market position in the coming quarters.